Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells
作者： Ana Valdehita , María J. Carmena , Beatriz Collado , Juan C. Prieto , Ana M. Bajo
DOI: 10.1016/J.REGPEP.2007.06.006
关键词:
摘要: Previous studies have shown that vasoactive intestinal peptide (VIP) and its receptors (VPAC(1) VPAC(2) receptors) are involved in promotion growth of many human tumours including breast cancer. Here we investigated whether VIP regulates the expression main angiogenic factor, vascular endothelial cell factor (VEGF) oestrogen-dependent (T47D) oestrogen-independent (MDA-MB-4687) cancer cells. Semiquantitative quantitative real-time RT-PCRs were used at mRNA level whereas enzyme immunoanalysis was performed protein level. Both lines expressed VPAC(1) (but not VPAC(2)) functional as by stimulation adenylate cyclase activity. induced VEGF both levels following a time-dependent pattern. The responses faster T47D than MDA-MB-468 observed regulation appears to be modulated least cAMP/protein kinase A (PKA) phosphoinositide 3-kinase (PI3-K) signalling systems using specific inhibitors such H89 wortmannin. These actions suggest proangiogenic potential
elsevier.com
sci-hub.se 参考文章(53)
N. E. Kushlinskii, E. S. Gershtein, Role of Vascular Endothelial Growth Factor during Breast Cancer Bulletin of Experimental Biology and Medicine. ,vol. 133, pp. 521- 528 ,(2002) , 10.1023/A:1020259702427
Michael Birrer, Illana Gozes, Sonia Jakowlew, Mati Fridkin, Yehoshua Gozes, Toyoaki Hida, Terry W. Moody, Jean C. Reubi, Hasan Zia, Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Research. ,vol. 56, pp. 3486- 3489 ,(1996)
P de Cremoux, C Gespach, F Calvo, W Bawab, Pharmacology, Molecular Identification and Functional Characteristics of Vasoactive Intestinal Peptide Receptors in Human Breast Cancer Cells Cancer Research. ,vol. 48, pp. 5079- 5083 ,(1988)
Michael John Fry, Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Research. ,vol. 3, pp. 304- 312 ,(2001) , 10.1186/BCR312
Barbro Linderholm, Kjell Grankvist, Nils Wilking, Mikael Johansson, Björn Tavelin, Roger Henriksson, Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment Journal of Clinical Oncology. ,vol. 18, pp. 1423- 1431 ,(2000) , 10.1200/JCO.2000.18.7.1423
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun, Cancer statistics, 2006. CA: A Cancer Journal for Clinicians. ,vol. 56, pp. 106- 130 ,(2006) , 10.3322/CANJCLIN.56.2.106
Oscar Gómez, José Antonio Balsa, Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen. Endocrinology. ,vol. 144, pp. 4403- 4409 ,(2003) , 10.1210/EN.2003-0261
Gilberto de Castro Junior, Fabio Puglisi, Evandro de Azambuja, Nagi S. El Saghir, Ahmad Awada, Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the do ut des paradigm) Critical Reviews in Oncology Hematology. ,vol. 59, pp. 40- 50 ,(2006) , 10.1016/J.CRITREVONC.2006.02.007
Beatriz Collado, María Carmena, Manuel Sánchez-Chapado, Antonio Ruíz-Villaespesa, Ana Bajo, Ana Fernández-Martínez, Jozsef Varga, Andrew Schally, Juan Prieto, Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology. ,vol. 26, pp. 1629- 1635 ,(2005) , 10.3892/IJO.26.6.1629
Marchessini Casibang, Sally Purdom, Sonia Jakowlew, Len Neckers, Farah Zia, Pazit Ben-Av, Tim Hla, Liang You, David M Jablons, Terry W Moody, None, Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. ,vol. 31, pp. 203- 212 ,(2001) , 10.1016/S0169-5002(00)00168-9